BRIEF-Neurogene Inc - Participant In Neurogene's Phase 1/2 Trial For Rett Syndrome Dies

Neurogene Shares Shares Down 5.5% After the Bell Following Announcement That Trial Participant Died, FDA Allowing It to Proceed With Trial for Rett Syndrome

Neurogene Inc - Participant in Neurogene's Phase 1/2 Trial for Rett Syndrome Dies

Neurogene Inc. Faces Uncertainty with NGN-101 Program Amid FDA Challenges and Strategic Hurdles

Neurogene Price Target Maintained With a $55.00/Share by HC Wainwright & Co.

Neoleukin Therapeutics GAAP EPS of -$1.19 in-line

Neurogene Inc reports results for the quarter ended September 30 - Earnings Summary

Neurogene Q3 2024 GAAP EPS $(1.19) Beats $(1.22) Estimate

BRIEF-Neurogene Q3 Net Income USD -20.217 Million

Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates

Neurogene Inc Q3 Shr View $-1.22 -- Lseg Ibes Data

Neurogene Inc: Strong Cash Position Provides Runway Into Second Half of 2027

Neurogene Q3 Net Income USD -20.217 Million

Press Release: Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates

Neurogene Shares Down 35.1% After Co to Stop Giving High Dose of Gene Therapy to Patients in Study as It Investigates Possible Side Effect

Neurogene Shares Down 20.5% Premarket After Co to Stop Giving High Dose of Gene Therapy to Patients in Study as It Investigates Possible Side Effect

BUZZ-Neurogene drops after pausing part of gene therapy study due to serious side effect

Neurogene Receives FDA Approval to Proceed with Low-Dose Trial for Rett Syndrome Therapy

Neurogene Drops High-Dose Cohort of Gene-Therapy Study for Rett Syndrome